The panels yielded a diagnosis for 43 percent of more than 2,300 patients, at a cost between $75 and $150 per panel.
Compared to commercial exome kits and whole-genome sequencing, the firm's test had improved coverage in medically interpretable genes and the 56 ACMG genes.
Illumina's technology will be used to sequence DNA collected through the project, which aims to make genomic testing a standard in cancer care.
The investment bank noted Illumina's dominance in the NGS space and added that NIPT could be a near-term growth driver in the clinical sequencing market.
The new workflow, which was validated across three separate laboratories in New Jersey, is a critical step toward standardizing the use of RNA-seq in clinical genomics.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.